Abstract
Systems have been put in place in the Mayo Clinic Stem Cell Transplantation program
to reduce day-100 all-cause mortality. Currently our mortality has been reduced to
0.3%. Patients can undergo transplant as an outpatient, with a median hospital duration
of 0 days and only 25% of patients requiring a hospital stay of 5 days or greater.
Outpatient transplantation is safe and reduces patient-incurred costs.
Abbreviations and Acronyms:
ASCT (autologous stem cell transplant), MEL (melphalan), MM (multiple myeloma)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.Lancet. 1983; 2: 822-824
- Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N Engl J Med. 2017; 376: 1311-1320
- Single versus double autologous stem-cell transplantation for multiple myeloma.N Engl J Med. 2003; 349: 2495-2502
- High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.N Engl J Med. 2003; 348: 1875-1883
- Medical education in the United States. Introduction.JAMA. 1969; 210: 1455-1456
- Transplantation-related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.Am J Hematol. 2017; 92: E529-E533
- In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study.Biol Blood Marrow Transplant. 2017; 23: 1203-1207
- Management of myeloma-associated renal dysfunction in the era of novel therapies.Expert Rev Hematol. 2012; 5 (quiz 67-68): 51-66
Article Info
Footnotes
Potential Competing Interests: The authors report no competing interests.
Identification
Copyright
© 2017 Mayo Foundation for Medical Education and Research
